BBIO
BBIO clinical trials: BridgeBio Pharma, Inc.
Every trial on ClinicalTrials.gov where BridgeBio Pharma, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 43
- Trials linked
- 33
- As lead sponsor
- 10
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
BBIO on the catalyst calendar · BBIO registry changes
- Primary completion Aug 2030Sponsor estimatePhase 4NCT07695701Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisEidos Therapeutics, a BridgeBio company · Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)RecruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 3NCT07805356Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic HypoparathyroidismCalcilytix Therapeutics, Inc., a BridgeBio company · HypoparathyroidismRecruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2031Sponsor estimatePhase 2NCT05145010Extension Study of Infigratinib in Children With Achondroplasia (ACH)QED Therapeutics, a BridgeBio company · AchondroplasiaEnrolling by invitationBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 15, 2025ActualPhase 2NCT03536767Open-Label Study of AG10 in Patients With CardiomyopathyEidos Therapeutics, a BridgeBio company · Amyloid CardiomyopathyTerminatedBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2036Sponsor estimatePhase 2NCT07393373Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company · HypochondroplasiaEnrolling by invitationBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2037Sponsor estimatePhase 3NCT07116473To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)Eidos Therapeutics, a BridgeBio company · Amyloidosis in Transthyretin (TTR)Not yet recruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2031Sponsor estimatePhase 3NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantEidos Therapeutics, a BridgeBio company · AmyloidosisRecruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2025ActualPhase 3NCT05680818Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1Calcilytix Therapeutics, Inc., a BridgeBio company · Autosomal Dominant Hypocalcemia (ADH)Active, not recruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2/Phase 3NCT06873035An Interventional Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company · HypochondroplasiaEnrolling by invitationBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimateNo phase registeredNCT06410976Prospective Clinical Assessment Study in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company · HypochondroplasiaRecruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2030Sponsor estimatePhase 2NCT07169279Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)QED Therapeutics, a BridgeBio company · AchondroplasiaRecruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2028Sponsor estimateNo phase registeredNCT05227287ADH1 and ADH2 Disease Monitoring Study (DMS)Calcilytix Therapeutics, Inc., a BridgeBio company · Autosomal Dominant HypocalcemiaActive, not recruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2/Phase 3NCT07080385Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)Calcilytix Therapeutics, Inc., a BridgeBio company · Autosomal Dominant Hypocalcemia Type 1 (ADH1)RecruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 27, 2025ActualNo phase registeredNCT04035811Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)QED Therapeutics, a BridgeBio company · AchondroplasiaCompletedBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2025ActualPhase 3NCT06164951A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaQED Therapeutics, a BridgeBio company · AchondroplasiaCompletedBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 21, 2024ActualPhase 2NCT04265651Study of Infigratinib in Children With AchondroplasiaQED Therapeutics, a BridgeBio company · AchondroplasiaCompletedBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 15, 2028Sponsor estimatePhase 3NCT04988386Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR ParticipantsEidos Therapeutics, a BridgeBio company · Amyloid Cardiomyopathy, Transthyretin-RelatedActive, not recruitingBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2024ActualPhase 1NCT05480865SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C MutationNavire Pharma Inc., a BridgeBio company · Solid Tumor, AdultTerminatedBBIOLeadAMGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 12, 2024ActualPhase 1NCT05375084SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationNavire Pharma Inc., a BridgeBio company · Non Small Cell Lung CancerTerminatedBBIOLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 22, 2024ActualPhase 1NCT04528836First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid TumorsNavire Pharma Inc., a BridgeBio company · Tumor, SolidTerminatedBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2023ActualPhase 2NCT04581629Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1Calcilytix Therapeutics, Inc., a BridgeBio company · Autosomal Dominant Hypocalcemia (ADH)CompletedBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2024Sponsor estimatePhase 3NCT04418024Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyEidos Therapeutics, a BridgeBio company · Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyWithdrawnBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 3NCT04882735Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)Eidos Therapeutics, a BridgeBio company · Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyWithdrawnBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 4, 2021ActualPhase 1NCT04769479A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy SubjectsEidos Therapeutics, a BridgeBio company · AmyloidosisCompletedBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2018ActualPhase 1NCT03294707Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10Eidos Therapeutics, a BridgeBio company · Amyloid Cardiomyopathy, Transthyretin-RelatedCompletedBBIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 18 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner